66,998 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Purchased by BNP Paribas Financial Markets

BNP Paribas Financial Markets acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 66,998 shares of the company’s stock, valued at approximately $1,578,000. BNP Paribas Financial Markets owned approximately 0.07% of Dyne Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the business. Bank of New York Mellon Corp increased its holdings in Dyne Therapeutics by 0.3% in the 4th quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock worth $5,532,000 after buying an additional 698 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after purchasing an additional 721 shares during the last quarter. KBC Group NV boosted its position in Dyne Therapeutics by 45.3% in the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the last quarter. E Fund Management Co. Ltd. boosted its position in Dyne Therapeutics by 11.8% in the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $279,000 after purchasing an additional 1,249 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Dyne Therapeutics by 11.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company’s stock worth $508,000 after purchasing an additional 2,265 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Trading Up 0.8%

NASDAQ DYN opened at $11.83 on Monday. The stock’s 50 day moving average is $10.36 and its 200 day moving average is $17.35. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $47.45. The stock has a market cap of $1.34 billion, a PE ratio of -3.32 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). On average, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company’s stock, valued at $2,777,263.65. The trade was a 1.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders have sold 6,237 shares of company stock valued at $77,760. Corporate insiders own 14.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on DYN shares. Piper Sandler dropped their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Scotiabank started coverage on Dyne Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price on the stock. Chardan Capital reissued a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Friday, May 9th. BMO Capital Markets started coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 target price on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $46.85.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.